Gastroenterology
William Fusco, gastroenterologist at Policlinico Universitario Agostino Gemelli, highlighted a recently published pilot study on post-infectious irritable bowel syndrome (IBS) framed within microbial precision medicine and biomarker-driven care.
Changes in gut bacteria raise a child’s chances of developing IBD later in life, offering clues to why the conditions sometimes runs in families.
Francesca Ponziani from Gemelli University Hospital (Italy) highlights how the gut microbiota can become a clinical tool for identifying and stratifying patients, clarifying pathogenic mechanisms, and opening up new therapeutic…
Federica Facciotti, from University of Milano Bicocca, focuses on how the gut microbiota interacts with immune activation, shaping both chronic inflammatory intestinal disorders and oncology, particularly colorectal cancer.
Gut bacteria help protect the liver by breaking down sorbitol, a sugar made from glucose in the gut.
A gut bacterium, Clostridium steroidoreducens, can chemically modify steroid hormones, including those used to treat IBD.
L. mucosae and L. ruminis can produce serotonin in the gut, where it promotes nerve growth and regulates intestinal motility.
Researchers have found that certain gut bacteria and their metabolites differ between IBS subtypes.
Controlling cadaverine levels and the gut bacteria that produce it could help regulate immune cell metabolism and inflammation.
Emilia Ghelardi, Professor of Microbiology and Molecular Microbiology at the University of Pisa, explains how pathogens can actively disrupt the integrity of the commensal community.
